Literature DB >> 30142304

Clinical evaluation and in-vivo analysis of the performance of a fractional infrared 1550 nm laser system for skin rejuvenation.

W James Tidwell1, Courtney Green1, Daniel Jensen1, E Victor Ross1.   

Abstract

Background: This study was done to demonstrate the safety and efficacy of a novel fractional 1550 nm laser device with a rolling mechanism (FRAX1550 Ellipse Medical, Horsholm, Denmark).
Objectives: To evaluated the effectiveness of the 1550 nm device for improvement in wrinkles, pigmentation, and texture on a six point (-1 to 4) global improvement scale.
Methods: Five female subjects between the ages of 44 and 71 years, with visible wrinkles and/or dyspigmentation were enrolled in the study. Two full face treatments were performed four weeks apart Follow-up visits at 1 and 3 months posttreatment were scheduled for photographic assessments. Assessment of improvement were performed by the investigators and two blinded evaluators through use of a six-point scale.
Results: All subjects demonstrated improvement in all monitored parameters. The mean improvement scores were: wrinkles 1.6, skin texture 1.8, and pigmentation 1.7. All score improvements were statistically significant. Biopsy was performed on one patient immediately post-treatment and showed 800 μ penetration depth at a treatment level of 88 mJ and 400 μ at 44 mJ. Conclusions: The new rolling fractional 1550 nm laser device from this study offers improvement of aging facial skin with short downtime and minimal side effects.

Entities:  

Keywords:  Fractional lasers; Nonablative laser; photorejuvenation

Mesh:

Year:  2018        PMID: 30142304     DOI: 10.1080/14764172.2018.1511915

Source DB:  PubMed          Journal:  J Cosmet Laser Ther        ISSN: 1476-4172            Impact factor:   2.247


  1 in total

1.  Combination therapy using non-ablative fractional laser and intralesional triamcinolone injection for hypertrophic scars and keloids treatment.

Authors:  Jongweon Shin; Jin Tae Cho; Song I Park; Sung No Jung
Journal:  Int Wound J       Date:  2019-09-02       Impact factor: 3.315

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.